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Abstract
Parkinson disease (PD) is a common disorder that leads to motor and cognitive disability. We
performed a genome-wide association study (GWAS) with 2000 PD and 1986 control Caucasian
subjects from NeuroGenetics Research Consortium.1–5 We confirmed SNCA2,6–8 and
MAPT3,7–9; replicated GAK9 (PPankratz+NGRC=3.2×10−9); and detected a novel association with
HLA (PNGRC=2.9×10−8) which replicated in two datasets (PMeta-analysis=1.9×10−10). We designate
the new PD genes PARK17 (GAK) and PARK18 (HLA). PD-HLA association was uniform
across genetic and environmental risk strata, and strong in sporadic (P=5.5×10−10) and late-onset
(P=2.4×10−8) PD. The association peak was at rs3129882, a non-coding variant in HLA-DRA.
Two studies suggested rs3129882 influences expression of HLA-DR and HLA-DQ.10,11 PD
brains exhibit up-regulation of DR antigens and presence of DR-positive reactive microglia.12
Moreover, non-steroidal anti-inflammatory drugs (NSAID) reduce PD risk.4,13 The genetic
association with HLA coalesces the evidence for involvement of the immune system and offers
new targets for drug development and pharmacogenetics.
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Late-onset sporadic PD was long believed to be environmental with no genetic component.
14,15 The initial samples that eventually coalesced to form the NGRC dataset was the basis
for the first of a series of family studies that revealed the genetic component in PD.1,16 In
the last decade, mutations in several genes were identified as causes of early-onset and
Mendelian forms of PD, and polymorphisms in the SNCA (chromosome 4q21) and MAPT
(17q21.1) regions were established as risk factors for common non-Mendelian PD.2,3,6–
9,17 PD risk is also associated, inversely, with cigarette smoking, caffeinated-coffee
consumption and NSAID use.4,13,18 Common late-onset PD is currently thought to result
from an interplay of genetic susceptibility and environmental exposures, and data in support
of this notion is beginning to emerge.5
A GWAS conducted in Japan identified two novel PD loci.19 Five GWAS have been
performed in Caucasians, most confirmed the known associations with SNCA and MAPT,
but none identified any new genes that reached genome-wide significance.7–9,20,21 We
investigated whether the genetic component in PD in Caucasians was due to the genes that
have already been identified. Using NGRC data, we estimated heritability before and after
excluding the known pathogenic and susceptibility loci. Heritability of PD declined from 0.6
(P<0.0001) to 0.4 (P=0.01), but was still significant, suggesting additional unidentified
genes exist.22
We performed a GWAS with 2,000 PD patients, 1,986 control subjects, and 811,597 single
nucleotide polymorphisms (SNPs) (Supplementary Table 1). Subjects were recruited from
the NGRC clinics in Oregon, Washington, New York and Georgia, using uniform criteria
for diagnosis,23 subject selection, data collection and DNA preparation.2–5 25% of PD
diagnoses change within the initial 5.4 years;24 therefore follow-up substantially reduces
heterogeneity. Mean disease duration at enrollment was 8 years, eliminating most early
misdiagnoses, and with an additional mean follow-up of 4 years, we were able to exclude
another 47 misdiagnoses before GWAS. Controls were selected by the same investigators
and from the same geographic regions as patients. At enrolment, they were on average 12
years older than the patients’ onset age, which increased power by reducing the likelihood
that controls were at risk but too young to have developed symptoms. We used the Illumina
HumanOmni1-Quad_v1-0_B genotyping array and achieved call rate of 99.92% and
reproducibility rate of ≥99.99%. Association analyses were performed using PLINK
V1.07.25 We adjusted all analyses for four covariates: age to avoid survival bias, sex
because PD affects more men than women, and two principal components (PC1, PC2) which
marked significant genetic substructure among Caucasian Americans of European descent
(Supplementary Figure 1). Our GWAS confirmed the known PD-susceptibility regions at
SNCA (P=3.4×10−11) and MAPT (P=1.3×10−6), as we had previously reported.2,3
We uncovered a novel genetic association with PD in the HLA region (chromosome
6p21.3). The peak significance was at the rs3129882 polymorphism in intron 1 of HLA-
DRA gene. The association was genome-wide significance even after adjusting for four
covariates (sex, age, PC1, PC2), P=2.9×10−8 (Table 1, Fig. 1 & 2 and Supplementary Fig.
2). 107 HLA SNPs reached P<10−3 for association with PD. We replicated association of
rs3129882 in two independent data sets8,9 (Table 1, ORMeta-analysis=1.26,
PMeta-analysis=1.9×10−10). The risk allele was the same in all datasets and was in Hardy-
Weinberg equilibrium (HWE) in cases and in controls which in addition to the visual
inspection of intensity plots supports no major problems with genotyping. Stratified analysis
by family history, age at onset, gender and environmental exposures revealed ubiquitous
associations across strata, and tests of heterogeneity across strata were not significant
(Supplementary Table 2). Associations were particularly strong for sporadic PD
(P=5.5×10−10), late-onset PD (P=2.4×10−8), and men (P=1.1×10−7). Most cases of PD are
sporadic, late-onset and affect men more than women. There was no evidence for gene-
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environment or gene-gene interaction between rs219882 and smoking (P=0.42), coffee
(P=0.55), NSAIDs (P=0.65), SNCA rs356220 (P=0.78) or MAPT rs199533 (P=0.24).
To explore for other true signals that may not have reached GW significance, we performed
in silico replication and Meta-analysis of the most significant (P<10−5) SNPs in NGRC,
using a publically available dataset from dbGaP (CIDR: Genome Wide Association Study in
Familial Parkinson Disease) which has been published by Pankratz et al9. SNPs that
replicated were in HLA (six SNPs in addition to rs3129882), SNCA and MAPT regions
(Supplementary Table 3). One SNP (rs2046571) in the Hyaluronan synthase 2 (HAS2) gene
region on chromosome 8 was marginally significant in CIDR, but did not reach genome-
wide significance in Meta-analysis (3.6×10−7).
We used NGRC to replicate findings of previous PD GWAS (Supplementary Table 4). We
confirmed the association of PD with cyclin G-associated kinase (GAK, 4p16,
Supplementary Figure 3), as suggested by Pankratz et al.9 (rs11248051 PNGRC=3.1×10−4,
ORNGRC+Pankratz =1.46, PNGRC+Pankratz =3.2×10−9). Satake et al.19 reported PARK16
(1q32), BST1 (4p15) and common variants (not rare mutations that cause Mendelian-PD) in
LRRK2 (12q12) as new PD risk factors in the Japanese, and the accompanying GWAS by
Simon-Sanchez et al.7 suggested these associations extend to Caucasians. We did not
replicate PARK16 (ORs were in opposite direction from Satake results, P=0.03–0.15). Two
of the six reported BST1 SNPs reached P<0.05 in our data. LRRK2 variants that were
reported by Simone-Sanchez et al. were not significant in NGRC (P=0.57 & 0.69); however,
three LRRK2 SNPs from the Satake’s study yielded P<0.05 in NGRC, and several other
LRRK2 SNPs reached P~10−3. In NGRC, 1% of sporadic and 3% of familial PD have rare
LRRK2 mutations.26 Since LRRK2 mutations are known to cause Mendelian-PD,
association between common LRRK2 variants and non-Mendelian PD warrants follow up.
SNCA, MAPT, GAK and HLA each have a modest effect on PD risk, but when considered
together, the cumulative effect can be substantial (Supplementary Fig. 4). To explore the
combined effects of the four genes, we classified the subjects by the total number of risk
alleles that they carry (0 to 8). Compared to subjects who had one or no risk allele, the risk
of PD was doubled for individuals who had four risk alleles (OR=2.49, 95%CI=1.79–3.47,
P=6.5×10−8), and was five-fold higher for individuals who had six or more risk alleles
(OR=4.95, 95%CI=3.20–7.64, P=5.5×10−13). Thus our data support the long held notion
that PD risk is due to cumulative effects of risk factors with modest individual effect.
A persistent problem in genetic association studies is inconsistent reproducibility which
often arises from hidden genetic variation, i.e., population substructure. We investigated
population structure in depth, using Genomic Control (λ)27 and principal component
analysis (PCA),28 augmented with self-reported ethnic and geographic origin
(Supplementary Fig 1). Genomic inflation factor was λ=1.03 (Supplementary Fig 2). When
compared to HAPMAP reference samples, NGRC clustered well with Caucasians. However,
within NGRC, which is a typical mixed Caucasian European-American population, we
found evidence for significant genetic diversity (PC1, P=2.9×10−5, Eigen-value=3.97; PC2,
P=0.007, Eigen-value=1.26). Using self reported data on ancestry, we determined that the
primary clusters correlate with Ashkenazi-Jewish and non-Jewish ancestry, and that the
residual diversity in the larger non-Ashkenazi population correlates with the European
country from which the subjects’ ancestors had immigrated to the US (Supplemental Fig 1
a-d). Demonstrating the existence of a significant substructure within Americans of
European descent, although not surprising, has not been reported before, and may be a major
reason for inconsistent findings in genetic association studies. The frequency of rs3129882
risk allele varied significantly in controls (P=0.0007), from 0.36 in Washington to 0.46 in
New York. Similarly, we observed a frequency gradient across Europe, low in subjects with
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Northern-European ancestry and high in Southern-Europeans, particularly Italians
(Supplementary Table 2). According to the US census, 14.4% of New Yorkers are Italian vs.
5.6% nationwide, which may explain the high allele frequency in NY. Within each
subpopulation (US state, or original country) patients had a higher frequency of the HLA
risk allele than controls, which supports association of HLA with PD. However, because of
the variable allele frequency, if the population substructure within European Americans is
not taken into account, other studies may find no difference or even an inverse association of
this allele with disease depending on the mixed origins of their cases and controls. Future
studies of HLA and PD will therefore require careful attention to ethnic and geographic
origin of the American subjects of European descent.
To assure that the association with HLA was not confounded by population substructure, we
corrected all analyses for the two significant PC that marked Jewish ancestry and European
country of origin. Additionally, we confirmed that the association of PD with rs3129882 was
present in genetically-defined core subsamples of both Jewish (0.04≤PC1≤0.055 and
0.001≤PC2≤0.013) and non-Jewish (−0.0075≤PC1≤0.0025 & −0.005≤PC2≤0.003) clusters
(Supplementary Table 2, Supplementary Fig 1c). Lower-order PCs were not significant
(PC3, P=0.32, Eigen-value=1.11) indicating that the bulk of genetic diversity within NGRC
has been identified and accounted for. We investigated and ruled out the concern that the
association of HLA with PD was driven by the association of HLA with PCs
(Supplementary Fig. 5, 6, Supplementary Table 5).
The HLA variant that displays the strongest statistical association with PD, rs3129882, is a
non-coding polymorphism in intron-1 of HLA-DRA gene (Fig. 2). The protein chains
encoded by the closely linked HLA-DRA and HLA-DRB form the class II HLA-DR
antigens, which are expressed by antigen presenting cells including microglia in brain, and
interact with T-cell receptors. HLA-DRB chains are highly variable and have been
associated with numerous disorders. HLA-DRA on the other hand is practically
monomorphic and therefore has not been investigated for disease-association. The
conventional explanation for our finding is that PD is associated with a classical
polymorphic HLA antigen and that rs3129882 is a proxy. Alternatively, PD-association with
an intronic DRA variant may represent involvement of regulatory elements, which would be
in line with PD-specific over-expression of DR antigens in substantia nigra.29 We used
University of Chicago’s expression quantitative trait loci (eQTL) data repository (http://
eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/) to identify potential transcriptional variance
associated with rs3129882. Two eQTL analyses, one using microarrays and the other RNA-
seq, had identified rs3129882 as a cis-acting regulatory variation that correlated significantly
(P=10−7 to 10−4) with expression levels of HLA-DRA, HLA-DQA2, and HLA-DRB5.10,11
One study reports the correlation as exon QTL which suggests the variant also affects
alternative splicing expression.10,11
The evidence for genetic association with HLA, particularly when obtained from a
hypothesis-free GWAS, lends strong and independent support to the involvement of neuro-
inflammation12 and humoral immunity30 in PD pathogenesis. Studies have shown elevated
DR expression in the brain29 and cerebrospinal fluid31 of PD patients. Sustained presence
of reactive DR-positive microglia has been observed in substantia nigra of PD patients,29 as
well as animals32 and humans33 affected with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) induced parkinsonism. It is postulated that the chronic immune
activation and neuro-inflammation is in response to an initial trigger, possibly related to
alpha-synuclein accumulation, and produce neurotoxins and oxidative damage that could kill
neurons. From a therapeutic perspective, vaccination aimed at neutralizing neuro-immune
dysfunction was recently shown to attenuate neurodegeneration in a PD model;34
furthermore, NSAID use is associated with reduced risk of developing PD in humans.4,13
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The novel association with HLA highlights the involvement of an important biological
pathway in the etiology of PD and a drug target that will stimulate research towards new
therapies.
Methods
Human Subjects
Study was approved by Human Subject Committees at participating institutions. Patients
and control subjects were recruited from eight NGRC-affiliated neurology clinics in Oregon,
Washington, Georgia and New York. Methods were standardized across NGRC. Patients
were diagnosed using the modified UK Brain Bank criteria.23 Controls were community
volunteers and patient spouses; 353 (ages 67–90; mean 86.3±4.1 years) were evaluated by
neurologists in Oregon and were free of neurodegenerative disease, the remaining 1633
(ages 21–90, mean 67.0±12.0 years) self-reported as neurologically healthy. GWAS subjects
met seven criteria: (1) Self-reported Caucasian, non-Hispanic, of European origin. (2)
Patients with current diagnosis of PD, excluding those whose initial PD diagnosis changed
during the ~12 years of follow up. (3) DNA extracted from whole blood, unamplified,
concentration ≥ 50ng/μl. (4) Age at blood draw ≥21 years. (5) Known gender. (6) Known
age at onset (one missing). (7) No blood-relation to other subjects. We had data on smoking,
coffee, and NSAIDs on ~3,000 subjects and on country of ancestral origin for 2,080
subjects. 112 subjects reported as Ashkenazi Jewish (129 were Jewish according to PCA).
Genotyping
To reduce plate effects, DNA samples were randomized on genotyping plates by case-
control status, recruitment site, control subjects who were healthy at age ≥85 years, DNA
extraction method, and DNA storage time. Samples were genotyped at the Johns Hopkins
Center for Inherited Disease Research (CIDR). Data was released for 4,013 study samples
(99.5% of attempted samples). Study samples, 90 duplicates, and 170 HapMap controls (151
CEU; 12 YRI, 3 JPT, 4 CHB) were genotyped using Illumina HumanOmni1-Quad_v1-0_B
BeadChips (Illumina, San Diego, CA, USA) and the Illumina Infinium II assay protocol.
Genotype cluster definitions for each SNP were determined using Illumina BeadStudio
Genotyping Module version 3.3.7 and the combined intensity data from all released samples.
Genotypes were not called if the quality threshold (Gencall score) was <0.15. Genotype data
was released for 1,012,895 SNPs (99.65% of attempted). SNP assay failure criteria were:
call rate <85%, cluster separation <0.2, >1 HapMap replicate error, >3% (autosomal) or
>4% (X) difference in call rate between genders, >0.3% male AB frequency (X), or >8.8%
(autosomal) or >13.2% (XY) difference in AB frequency. Y chromosome and mitochondrial
SNPs were manually reviewed and clusters adjusted or genotypes dropped as appropriate.
The mean non-Y SNP call rate and mean sample call rate were both 99.9% for the released
dataset. Study duplicate reproducibility was ≥99.99% (Supplementary Table 1).
Statistical Analysis
Sex was determined by estimating X chromosome homozygosity and compared to self-
reported gender; there was no discrepancy. We identified and excluded 1 patient and 3
controls who were inadvertently enrolled twice, and 13 cases and 10 controls for cryptic
relatedness (PI-HAT>0.15). The final N for analysis was 2,000 patients and 1,986 controls.
SNPs were excluded if MAF<0.01, call-rate<99%, HWE<10−6, MAF difference in males
vs. females >0.15, or missing rate in PD vs. control P<10−5. 811,597 SNPs passed quality-
control; with mean call rate of 99.92%. PCA was conducted with HelixTree
(www.goldenhelix.com) using a pruned subset of 104,064 SNPs. Pruning was carried-out
using PLINK with autosomal SNPs (MAF≥0.05, call rate ≥95%). We used a 50-SNP
sliding-window that shifted 5 SNPs with each move and recursively removed SNPs with
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r2≥0.2, followed by a second round using a 138 SNP sliding-window, resulting in 104,064
SNPs.
Association was tested under an additive model using logistic regression in PLINK V1.07.
The analyses were adjusted for sex, age, PC1 and PC2. Linkage disequilibrium (LD) was
assessed using Haploview V4.135 and LocusZoom (http://csg.sph.umich.edu/locuszoom/).
For replication of NGRC results, we chose datasets that (a) were published by peer review,
(b) had genotyped rs3129882, and (c) were Caucasian. Among four publically-available
GWAS only “CIDR: Genome Wide Association Study in Familial Parkinson Disease (PD)”
by Pankratz et al.9 met our criteria. Two other GWAS have been published;7,8 one was
available to us and was used as second replication.8 We applied the same sample and SNP
quality-control filters to replication data sets as we did for NGRC, hence our results may
vary slightly from their published results. Each replication dataset was individually tested
using the tests and adjustments used by authors in their original report. Breslow-Day test-
statistics was used to test heterogeneity across three datasets (P=0.6). We performed
individual level Meta-analysis using Cochran-Mantel- Haenszel (CMH) test statistics
accounting for study and gender. Chi-square test was used to test differences in MAF across
disease, ethnic, and geographic strata.
To replicate previously reported GWAS findings, we used genotyped data when available
and imputed SNPs that were not present on the array. We used PLINK for imputation, and
included SNPs that had call rate ≥95% (information content metric value was >0.8). Meta-
analysis was performed using CMH when individual level data was available, otherwise, we
used aggregate (OR) data (PLINK was used). We used Breslow-Day test-statistics to test
between-study heterogeneity for individual-level data and Q-test for aggregate-level data.
We used logistic regression to test combined effects of four loci (SNCA, MAPT, GAK,
HLA). Subjects were classified by the total number of risk alleles (n) that they possessed
(minimum=0, maximum=8); carriers of 0 or 1 risk allele were combined due to small
numbers and set as the reference for comparison; carriers of 6 or more alleles were also
combined due to small numbers at the extremes. Tests were performed comparing subjects
with ‘n’ risk alleles to the reference group.
Access to material
Data are publically available via dbGaP (http://www.ncbi.nlm.nih.gov/gap).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genome-wide association P-values
The Manhattan plot shows the P-values for association of 811,597 SNPs with PD. SNPs that
surpass genome-wide significance (P<5×10−8) were on chromosomes 4 (SNCA region) and
6 (HLA-DRA). SNCA was known to be associed with PD, the HLA association is novel.
The other known PD-associated region is on chromosme 17 (MAPT region) which
replicated at P=1.3×10−6.
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Figure 2. Signals of PD-association within HLA
A one megabase (MB) region was defined centered on the association peak, rs3129882 in
intron 1 of HLA-DRA, spanning from base pair (BP) position 32,017,508 to 33,017,508.
The top panel shows all SNPs in this region plotted according to the significance of their
association with PD and color-coded according to their linkage disequilibrium (r2) with the
most significant SNP, rs3129882. Note that rs3129882 is not strongly correlated (defined as
r2≥ 0.8)with any other HLA variant. The LocusZoom software used here calculates r2 using
the HapMap CEU data. SNPs shown in grey were on the Illumina OMNI chip but not on
HAPMAP thus r2 was not calculated with this method; however, using the Haploview
software and the NGRC data to estimate r2, none of the variants was strongly correlated with
rs3129882 (r2<0.6, Supplementary Fig. 6). The bottom panel shows the genes in the region,
including the closely linked polymorphic HLA-DRB and DQB loci, and DRA, DRB5, and
DRQA2 whose expression is correlated with the variation at rs3129882.
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